Paradigm Biopharmaceuticals (ASX:PAR) has commenced dosing participants in both Australia and the US in its pivotal PARA_OA_012 Phase 3 trial of injectable PPS (iPPS) for knee osteoarthritis. Following a deliberate site-initiation phase, large-scale recruitment will now be supported by Hope4OA, Citeline (US) and Medimark (Australia). Early screening shows improved enrolment efficiency versus prior studies, reflecting FDA-supported protocol refinements. Paradigm expects nearly all sites active by end-October, with full enrolment of 466 patients in 1H CY2026 and interim analysis mid-2026, a key value inflection point.